Apoe Impact Study on Brain Structure and Function, in a Population 45 to 75 Years Old
1 other identifier
observational
575
1 country
1
Brief Summary
The purpose of this study is to investigate the influence of the APOE genotype on brain morphology, function and metabolism, related to other factors such as cognitive reserve, cognition and episodic memory, in subjects at greater risk of developing AD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2014
CompletedFirst Submitted
Initial submission to the registry
July 15, 2014
CompletedFirst Posted
Study publicly available on registry
July 23, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2015
CompletedMarch 3, 2017
March 1, 2017
1.2 years
July 15, 2014
March 1, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Hippocampal atrophy
2 years
Study Arms (1)
No treatment
The population of this study is 45 to 75 years old at the time of inclusion in the parent study (ClinicalTrials.gov ID: NCT01835717).
Eligibility Criteria
The population of this study is 45 to 75 years old at the time of inclusion in the parent study (ClinicalTrials.gov ID: NCT01835717), mostly sons and daughters of AD patients.
You may qualify if:
- Participant included in the study ClinicalTrials.gov ID: NCT01835717
- APOE genotype obtained before MRI acquisition
- Be willing to perform an MRI and agree to a 2 years longitudinal follow up
- Sign informed consent
You may not qualify if:
- Contraindication to MRI scanning: claustrophobia, pacemaker, history of ocular cerclage, heart valves, aneurysm clips and carrying any metal prosthesis incompatible with MRI.
- Incidental MRI findings that result in the images not being included in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Barcelonabeta Brain Research Center
Barcelona, 08003, Spain
Related Publications (2)
Ingala S, Mazzai L, Sudre CH, Salvado G, Brugulat-Serrat A, Wottschel V, Falcon C, Operto G, Tijms B, Gispert JD, Molinuevo JL, Barkhof F; ALFA Study. The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. Neurobiol Aging. 2020 Nov;95:104-114. doi: 10.1016/j.neurobiolaging.2020.06.015. Epub 2020 Jun 29.
PMID: 32791423DERIVEDBrugulat-Serrat A, Rojas S, Bargallo N, Conesa G, Minguillon C, Fauria K, Gramunt N, Molinuevo JL, Gispert JD. Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with Alzheimer's disease: a cross-sectional analysis from the ALFA (Alzheimer and Families) project. BMJ Open. 2017 Mar 24;7(3):e013215. doi: 10.1136/bmjopen-2016-013215.
PMID: 28341686DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Juan D Gispert, PhD
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
- PRINCIPAL INVESTIGATOR
José L Molinuevo, MD, PhD
IDIBAPS, Hospital Clinic de Barcelona, Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 15, 2014
First Posted
July 23, 2014
Study Start
April 1, 2014
Primary Completion
July 1, 2015
Study Completion
September 1, 2015
Last Updated
March 3, 2017
Record last verified: 2017-03